Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis
Open Access
- 11 June 2021
- journal article
- research article
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2021, 1-8
Abstract
Mycobacterium tuberculosis has developed extensive resistance to numerous antimycobacterial agents used in the treatment of tuberculosis. Insufficient intracellular accumulation of active moieties allows for selective survival of mycobacteria with drug resistance mutations and accordingly promotes the development of microbial drug resistance. Discovery of compounds with new mechanisms of action and physicochemical properties that promote intracellular accumulation, or compounds that act synergistically with other antimycobacterial drugs, has the potential to reduce and prevent further drug resistance. To this end, antimycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine derivatives. Compound selection was based on the presence of moieties with possible antimycobacterial activity, the inclusion of bulky lipophilic carriers to promote intracellular accumulation, and previously demonstrated bioactivity that potentially support inhibition of efflux pump activity. The most potent antimycobacterial demonstrated a minimum inhibitory concentration (MIC99) of 9.6μM against Mycobacterium tuberculosis H37Rv. Genotoxicity and inhibition of the cytochrome bc1 respiratory complex were excluded as mechanisms of action for all compounds. Inhibition of cell wall synthesis was identified as a likely mechanism of action for the two most active compounds (14 and 15). Compounds 5 and 6 demonstrated synergistic activity with the known Rv1258c efflux pump substrate, spectinomycin, pointing to possible efflux pump inhibition. For this series, the nature of the side chain, rather than the type of polycyclic carrier, seems to play a determining role in the antimycobacterial activity and cytotoxicity of the compounds. Contrariwise, the nature of the polycyclic carrier, particularly the azapentacycloundecane cage, appears to promote synergistic activity. Results point to the possibility of combining an azapentacycloundecane carrier with a side chain that promotes antimycobacterial activity to develop dual acting molecules for the treatment of Mycobacterium tuberculosis.Keywords
Funding Information
- National Research Foundation (117887, 86539)
- South African Research Chairs Initiative of the Department of Science and Technology (117887, 86539)
- South African Department of Science Innovation (117887, 86539)
This publication has 48 references indexed in Scilit:
- para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium tuberculosisJournal of Biological Chemistry, 2013
- A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosisPLOS ONE, 2013
- The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and TolerancePharmaceuticals, 2012
- Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell ScreeningChemistry & Biology, 2012
- Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug CandidatesAntimicrobial Agents and Chemotherapy, 2012
- SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agentsBioorganic & Medicinal Chemistry, 2011
- A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyNature Communications, 2010
- Drug efflux pump deficiency and drug target resistance masking in growing bacteriaProceedings of the National Academy of Sciences, 2009
- Characterization of the Mycobacterium tuberculosis iniBAC Promoter, a Promoter That Responds to Cell Wall Biosynthesis InhibitionJournal of Bacteriology, 2000